Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis

Zhou, Zheng Yi; Bensink, Mark E.; Hazra, Nisha C.; Xu, Chunyi; Hendry, Bruce; Sharpe, Claire C.; Zhou, Mo

Abstract

Background: Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a UK societal perspective.

Methods: We used the time trade-off (TTO) method to derive utility values for various health states in IgAN, defined based on chronic kidney disease (CKD) stage, proteinuria, dialysis, and nephrotic syndrome (CKD stages 1–4, proteinuria < 1 g/day vs ≥ 1 g/day; CKD stage 5, dialysis vs non-dialysis). We developed health state vignettes to describe typical symptoms and quality-of-life impairments of IgAN. Eligible participants from the UK general public completed a computer-assisted telephone interview. Estimated TTO utility values were reviewed against visual analogue scale (VAS)-derived values.

Results: In total, 200 participants were included in the study (mean age, 48.9 years; female, 59.0%). Mean (standard deviation [SD]) utility values were 0.84 (0.17) and 0.71 (0.23) for CKD stage 1/2 with proteinuria < 1 g/day and with proteinuria ≥ 1 g/day, respectively; 0.68 (0.23) and 0.61 (0.25) for CKD stage 3; and 0.55 (0.26) and 0.49 (0.27) for CKD stage 4. Mean (SD) utility of CKD stage 5 with and without dialysis was 0.38 (0.30) and 0.42 (0.28), respectively. The mean (SD) utility value of nephrotic syndrome was 0.43 (0.33).

Conclusions: Our results indicated that various IgAN health states are associated with impaired health status, with substantial utility decrements related to disease progression, elevated proteinuria, and nephrotic syndrome.

Citation

Zhou, Z. Y., Bensink, M. E., Hazra, N. C., Xu, C., Hendry, B., Sharpe, C. C., & Zhou, M. (2025). Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis. PharmacoEconomics - Open, 9(1), 83-92. https://doi.org/10.1007/s41669-024-00527-1

• Journal Article Type: Article
• Acceptance Date: Aug 28, 2024
• Online Publication Date: Sep 21, 2024
• Publication Date: 2025-01
• Deposit Date: May 27, 2025
• Publicly Available Date: Jun 6, 2025
• Journal: PharmacoEconomics - Open
• Electronic ISSN: 2509-4254
• Peer Reviewed: Peer Reviewed
• Volume: 9
• Issue: 1
• Pages: 83-92
• DOI: https://doi.org/10.1007/s41669-024-00527-1
• Public URL: https://nottingham-repository.worktribe.com/output/49555213
• Publisher URL: https://link.springer.com/article/10.1007/s41669-024-00527-1